[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA200500533A1 - Пептидные производные - ингибиторы слияния при вич-инфекции - Google Patents

Пептидные производные - ингибиторы слияния при вич-инфекции

Info

Publication number
EA200500533A1
EA200500533A1 EA200500533A EA200500533A EA200500533A1 EA 200500533 A1 EA200500533 A1 EA 200500533A1 EA 200500533 A EA200500533 A EA 200500533A EA 200500533 A EA200500533 A EA 200500533A EA 200500533 A1 EA200500533 A1 EA 200500533A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
mercury
hiv infection
peptide derivatives
derivatives
Prior art date
Application number
EA200500533A
Other languages
English (en)
Other versions
EA007918B1 (ru
Inventor
Донг Ксай
Хе Джанг
Original Assignee
Франтиэ Биотекнолоджиз Ко., Лтд.
Жиан, Хи
Донг Ксай
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Франтиэ Биотекнолоджиз Ко., Лтд., Жиан, Хи, Донг Ксай filed Critical Франтиэ Биотекнолоджиз Ко., Лтд.
Publication of EA200500533A1 publication Critical patent/EA200500533A1/ru
Publication of EA007918B1 publication Critical patent/EA007918B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к производным gp41-пептидов, которые представляют собой ингибиторы вирусной инфекции и/или обладают антифузогенными свойствами. В частности, данное изобретение относится к производным gp41-пептидов, обладающим ингибирующим действием по отношению к вирусу иммунодефицита человека (ВИЧ) и вирусу иммунодефицита обезьян (ВИО) и имеющим увеличенную продолжительность действия при лечении соответствующих вирусных инфекций.Отчет о международном поиске был опубликован 2004.08.12.
EA200500533A 2002-09-24 2003-09-23 Пептидные производные-ингибиторы слияния при вич-инфекции EA007918B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41279702P 2002-09-24 2002-09-24
PCT/US2003/029815 WO2004029201A2 (en) 2002-09-24 2003-09-23 Peptide derivative fusion inhibitors of hiv infection

Publications (2)

Publication Number Publication Date
EA200500533A1 true EA200500533A1 (ru) 2005-12-29
EA007918B1 EA007918B1 (ru) 2007-02-27

Family

ID=32043189

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500533A EA007918B1 (ru) 2002-09-24 2003-09-23 Пептидные производные-ингибиторы слияния при вич-инфекции

Country Status (15)

Country Link
US (3) US7575750B2 (ru)
EP (1) EP1542718B1 (ru)
JP (2) JP5385497B2 (ru)
CN (1) CN1327897C (ru)
AP (1) AP2203A (ru)
AU (2) AU2003275116A1 (ru)
BR (1) BR0314657A (ru)
CA (1) CA2500248C (ru)
CR (1) CR7806A (ru)
EA (1) EA007918B1 (ru)
ES (1) ES2558680T3 (ru)
IL (1) IL167527A (ru)
NZ (1) NZ539539A (ru)
WO (1) WO2004029201A2 (ru)
ZA (1) ZA200503118B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60229677D1 (de) 2001-05-31 2008-12-11 Conjuchem Biotechnologies Inc Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
EP1542718B1 (en) * 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection
CN100455594C (zh) * 2005-12-14 2009-01-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
MX2008008076A (es) * 2005-12-22 2008-11-28 Conjuchem Biotechnologies Inc Procesos para la produccion de conjugados preformados de albumina y un agente terapeutico.
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
WO2012022040A1 (zh) * 2010-08-19 2012-02-23 清华大学 Hiv-1病毒膜融合抑制剂及其应用
CN103664701A (zh) * 2013-11-29 2014-03-26 成都普康生物科技有限公司 [2-[2-(Fmoc-氨基)乙氧基]乙氧基]乙酸合成路线
CN114306225A (zh) * 2019-05-07 2022-04-12 前沿生物药业(南京)股份有限公司 稳定的艾博韦泰组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) * 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US3791667A (en) * 1972-05-04 1974-02-12 H Haviland Retractable vehicle passenger cushioning system
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
WO1992017492A1 (en) 1991-04-05 1992-10-15 Genentech, Inc. PLATELET AGGREGATION INHIBITORS HAVING HIGH SPECIFICITY FOR GP IIbIII¿a?
EP0831873A4 (en) * 1995-06-07 2002-07-17 Trimeris Inc COMBINATORY THERAPY FOR THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS
US5624902A (en) 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US6268479B1 (en) * 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
JP4209086B2 (ja) * 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド 長期持続性抗新脈管形成ペプチド
WO2000069911A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides
DE60026300T2 (de) * 1999-05-17 2006-11-16 Conjuchem, Inc., Montreal Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile
ATE443714T1 (de) * 1999-05-17 2009-10-15 Conjuchem Biotechnologies Inc Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US6750008B1 (en) * 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
CN1172717C (zh) * 2000-08-18 2004-10-27 清华大学 一种治疗艾滋病的药物及其制备方法
EP1542718B1 (en) * 2002-09-24 2015-11-11 Dong Xie Peptide derivative fusion inhibitors of hiv infection

Also Published As

Publication number Publication date
AU2010200823B2 (en) 2011-12-15
US20050089840A1 (en) 2005-04-28
EP1542718A2 (en) 2005-06-22
CN1327897C (zh) 2007-07-25
CN1668330A (zh) 2005-09-14
AU2010200823A1 (en) 2010-03-25
US20140187476A1 (en) 2014-07-03
WO2004029201A3 (en) 2004-08-12
US7575750B2 (en) 2009-08-18
WO2004029201A2 (en) 2004-04-08
ZA200503118B (en) 2006-11-29
EA007918B1 (ru) 2007-02-27
AP2203A (en) 2011-01-31
AP2005003291A0 (en) 2005-06-30
JP2006505536A (ja) 2006-02-16
CA2500248A1 (en) 2004-04-08
EP1542718B1 (en) 2015-11-11
US8470527B2 (en) 2013-06-25
AU2003275116A1 (en) 2004-04-19
JP2010209097A (ja) 2010-09-24
CR7806A (es) 2007-09-07
CA2500248C (en) 2013-03-19
JP5385497B2 (ja) 2014-01-08
US20110003735A1 (en) 2011-01-06
BR0314657A (pt) 2005-08-02
NZ539539A (en) 2006-11-30
EP1542718A4 (en) 2011-04-06
IL167527A (en) 2013-12-31
ES2558680T3 (es) 2016-02-08

Similar Documents

Publication Publication Date Title
CY1112267T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης ns3-σερινης του ιου ηπατιτιδας c
DE60229677D1 (de) Langwirkende Fusionspeptidinhibitoren gegen HIV-Infektion
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
EA200700243A1 (ru) Способы лечения гепатита с
NO20044897L (no) Hepatitt C virus inhibitorer
CY1112632T1 (el) Αναστολεις ασπαρτυλ πρωτεασης
CY1108036T1 (el) Κυτταρικη συσσωρευση φωσφονικων αναλογων ενωσεων αναστολεα πρωτεασης του ιου ανοσολογικης ανεπαρκειας του ανθρωπου (hiv) και οι ενωσεις ως τετοιες
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
MA31666B1 (fr) Cyclic peptide cxcr4 antagonists
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
CY1109012T1 (el) Παραγωγα νουκλεοσιδιου σαν αναστολεις της rna-εξαρτωμενης rna iϊκης πολυμepασης
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
ECSP093601A (es) Proteínas derivadas del virus del síndrome de mancha blanca y sus usos
BR9607625A (pt) Inibidores de protease retroviral sulfonamida hidroxietilamino de aminoácido heterociclocarbonila
WO2020252393A8 (en) Compositions and methods for the treatment of human immunodeficiency virus
EA200500533A1 (ru) Пептидные производные - ингибиторы слияния при вич-инфекции
DE60130641D1 (de) Pharmakologisch aktive antivirale peptide und methoden zu ihrer anwendung
MX9700414A (es) Agentes antivirales de difluoroestatona.
EA202191711A1 (ru) Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток
WO2003052122A3 (en) Gp41 inhibitor
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
ATE521640T1 (de) Anti-tsg101-antikörper und ihre verwendungen bei der behandlung von virusinfektionen
DE602005016552D1 (de) Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU